Abbreviations, links
& helpful information
Structured
- Agencies and Organisations
- Procedures and Submissions
- Clinical Trials and Development
- Chemistry – Manufacturing – Controls (CMC)
- GxP and Quality Management
- Pharmacovigilance
- Product Information
- Health Technology Assessment
- Intellectual Property
- Other
Regulatory Legislation
- EU EudraLex - ec.europa.eu/health/medicinal-products/eudralex_en
- US Code of Federal Regulations Title 21 Food and Drugs - accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
Regulatory and Clinical Glossary
Acronyms and Abbreviations
Please use ctrl + F to search through the Glossary
Alphabetical
A
- AADA – Abbreviated antibiotic drug application
- ABHI – Association of British Healthcare Industries
- ABPI – Association of the British Pharmaceutical Industry
- ACTD – ASEAN Common Technical Dossier
- ADI – Acceptable Daily Intake
- ADR – Adverse Drug Reaction
- AEMPS - Spanish Agency of Medicines and Medical Devices - aemps.gob.es
- AE – Adverse Event
- AIFA - Italian Medicines Agency - aifa.gov.it
- AIM – Active Ingredient Manufacturer
- ANDA – Abbreviated New Drug Application
- ANMAT - National Administration of Drugs, Foods and Medical Devices (Argentine) - anmat.gov.ar
- ANSM - National Security Agency of Medicines and Health Products (France) - ansm.sante.fr
- ANVISA - Brazilian Health Regulatory Agency - anvisa.gov.br
- API – Active Pharmaceutical Ingredient
- AQL – Acceptable Quality Level
- AR – Assessment Report (European Union)
- ASCPT – American Society for Clinical Pharmacology and Therapeutics
- ASMF – Active Substance Master File
- ATMPs – Advanced Therapy Medicinal Products
B
- BA – Bioavailability
- BAP – Biotechnology Action Programme
- BfArM – Federal Institute for Drugs and Medical Devices (Germany) - bfarm.de
- BIND – Biological Investigational New Drug
- BWP – Biotech Working Party (EMA)
C
- C&P – Chemistry and Pharmacy
- CA – Competent Authority
- CANDA – Computer Assisted New Drug Application
- CAP – Centrally Authorised Product
- CAPA – Corrective Action and Preventive Action
- CC – Candidate Country
- CCDS – Company Core Data Sheet
- CCG – Clinical Commissioning Group (UK)
- CD – Controlled Drug
- cGLP – Current Good Laboratory Practice
- cGMP – Current Good Manufacturing Practice
- Cl – Total Body Clearance
- CLO – Clinical Overview
- CLS – Clinical Summary
- CMC – Chemistry – Manufacturing – Controls
- CMP – Certificate of Medicinal Product
- COA – Certificate of Analysis
- CoFS – Certificate of Free Sale
- CP – Centralised Procedure (European Union)
- CP – Comparability Protocol (USA)
- CPP – Certificate of Pharmaceutical Product
- CQA – Clinical Quality Assurance
- CR – Controlled Release
- CRF – Case Report form
- CRO – Clinical Research Organisation
- CSI – Core Safety Information
- CSP – Core Safety Profile
- CSR – Clinical Study Report (European Union)
- CT – Clinical Trial
- CTA – Clinical Trial Application
- CTA – Clinical Trial Authorisation
- CTC – Clinical Trial Certificate (UK)
- CTD – Clinical Trials Directive
- CTD – Common Technical Document/Dossier
- CTMS – Clinical Trial Management System
- CTR – Clinical Trial Regulation (EU 536)
- CTS – Common Technical Specification
- CTX – Clinical Trial Exemption (UK)
- CVM – Center for Veterinary Medicine (US)
D
- DAE – Discontinuation due to an Adverse Event
- DDD – Defined Daily Dose
- DDPS – Detailed Description of Pharmacovigilance System
- DGRA – German Association Regulatory Affairs – dgra.de
- DIA – Drug Information Association - diaglobal.org
- DMF – Drug Master File
- DMS – Document Management System
- DP – Drug Product
- DS – Drug Substance
- DSUR – Development Safety Update Report
- DTC – Direct-to-consumer
- DUS – Drug Utilisation Study
E
- EA – Environmental Assessment
- EC – Ethics Committee
- eCTD – electronic Common Technical Document
- EDC – Electronic Data Capture
- EDMF – European Drug Master File
- EDT – Electronic Data Transfer
- EMA – European Medicines Agency - ema.europa.eu
- EPL – Effective Patent Life
- ePSUR – electronic Periodic Safety Update Report
- ERB – Ethical Review Board
- ESPAR – Executive Summary Pharmacovigilance Assessment Report
- EWG – Expert Working Group
- EWP – Efficacy Working Party
F
- FDA – Food and Drug Administration (US) – fda.gov
- FTE – Full Time Equivalent
G
- GCP – Good Clinical Practice
- GDP – Good Distribution Practice
- GGP – Good Guidance Practice
- GLP – Good Laboratory Practice
- GMP – Good Manufacturing practice
- G(P)VP – Good Pharmacovigilance Practice
- GRB – Global Regulatory Board
- GRP – Good Regulatory Practice
- GSP – Good Statistics Practice
H
- HCP – Healthcare Professional
- HEOR – Health Economics and Outcomes Research
- HREC – Human Research Ethics Committee
- HTA – Health Technology Assessment
- HTS – High-Throughput Screening
I
- IB – Investigator’s Brochure
- ICD/F – Informed Consent Document/Form
- ICSR – Individual Case Safety Report
- IDE – Investigational Device Exemption
- IDMP – Identification of Medicinal Products
- IEC – Independent Ethics Committee
- IMI – Innovative Medicines Initiative
- IMP – Investigational Medicinal Product
- IMPD – Investigational Medicinal Product Dossier
- IMRDF – International Medical Device Regulatory Forum
- IMS – Information Management Strategy
- INDA – Investigational New Drug Application (USA)
- INDC – Investigational New Drug Committee
- IP – Intellectual Property
- IPO – Intellectual Property Office
- IPR – Intellectual Property Rights
- IQM – Integrated Quality Management
- IRB – Institutional Review Board
- IRN – Incident Review Network
- IS – Internal Standard
- ISE – Integrated Summary of Efficacy
- ISRB – Integrated Summary of Risk Benefit
- ISS – Integrated Summary of Safety
K
- KOL – Key Opinion Leader
L
- LCM – Lifecycle Management
- LED – Least Effect Dose
M
- MA – Marketing Authorisation
- MAA – Marketing Authorisation Application (EU)
- MAH – Marketing Authorisation Holder
- MAIL – Medicines Act Information Letter (UK)
- MAL – Medicines Act Leaflet (UK)
- MDCG – Medical Device Coordination Group
- MDD – Medical Device Directive
- MDEG – Medical Device Expert Group
- MDLO – Medical Device Liaison Officer
- MDR – Medical Device Reporting
- MERS – Multi-agency Electronic Regulatory System
- MFDS - Ministry of Food and Drug Safety (Korea) - mfds.go.kr/eng
- MHRA – Medicines and Healthcare Products Regulatory Agency (UK) - gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- ML – Manufacturer’s Licence (UK)
- MOU – Memorandum of Understanding
- MPA – Medicines Product Agency (Sweden) - lakemedelsverket.se
- MRA – Mutual Recognition Agreement
N
- NAP – Nationally Authorised Product
- NBE – New Biological Entity
- NCE – New Chemical Entity
- NCO – Non Clinical Overview
- NCS – Non Clinical Summary
- NDAC – New Drug Advisory Committee (India)
- NED – Non Effect Dose
- NIMP – Non-Investigational Medicinal Product
- NME – New Molecular Entity
- NMPA - National Medical Products Administration (China) - english.nmpa.gov.cn
O
- OD – Orphan Drug
- ODA – Orphan Drugs Act (USA)
- ODD – Orphan Drug Designation
- OIA – Official Action Indicated
- OOS – Out of Specification
- OTC – Over-the-Counter
P
- P&R – Pricing and Reimbursement
- P – Pharmacy only
- P to GSL – Pharmacy to General Sales List
- PA – Product Authorisation
- PAI – Pre-Approval Inspection
- PAR – Preliminary Assessment Report
- PASS – Post Authorisation Safety Study
- PAT – Process Analytical Technology
- PDE – Personal Daily Exposure
- PFDD - Patient-Focused Drug Development
- PI – Prescribing Information
- PI – Production Information
- PIL – Patient Information Leaflet
- PIM – Product Information Management (EMA)
- PIP – Paediatric Investigation Plan (EMA)
- PMDA - Pharmaceuticals and Medical Devices Agency (Japan) - pmda.go.jp
- PMS Study – Post-Marketing Safety Study
- PMS – Postmarket(ing) Surveillance
- POM – Prescription-Only Medicine
- POM to P – Prescription-Only Medicine to Pharmacy
- PPI – Patient and Public Involvement (UK)
- PRSPH – Potential Serious Risk to Public Health
- PSMF – Pharmacovigilance System Master File
- PSP – Paediatric Study Plan (FDA)
- PTE – Patent Term Extension
- PUMA – Paediatric-Use Marketing Authorisation
- PV – Pharmacovigilance
- PVAR – Preliminary Variation Assessment Report
Q
- QA – Quality Assurance
- QbD – Quality by Design
- QC – Quality Control
- QMS – Quality Management System
- QOL – Quality of Life
- QoS – Quality overall Summary
- QP – Qualified Person
- QPPV – Qualified Person for Pharmacovigilance
- QRD – Quality Review of Documents [template]
R
- RA – Regulatory Affairs
- RCT – Randomised Controlled Trial
- RDE – Remote Data Entry
- RDS – Repeat Dose Study
- REACH – Registration, evaluation, authorisation and restriction of chemicals
- RI – Regulatory Intelligence
- RING – Regulatory Intelligence Network Group
- rINN – Recommended International Non-proprietary Name
- RMM – Risk Minimisation Measure
- RMP – Reference Medicinal Product
- ROI – Return on Investment
- RoW – Rest of World
- RP – Responsible Person
- RWD – Real World Data
- RWE – Real World Evidence
- Rx – Prescription
S
- S+T – Sampling and Testing
- SAG – Scientific Advisory Group
- SAP – Scientific Advice Procedure
- SAWP – Scientific Advice Working Party
- SMF – Site Master File
- SMO – Site Management Organisation
- SmPC – Summary of Product Characteristics
- SMQ – Standardised MedDRA query
- SOP – Standard Operating Procedure
- SPC - Supplementary Protection Certificate
- SPIN – Special Interest Network
- SSC – Scientific Steering Committee
- SWOTs – Strengths – Weaknesses – Opportunities – Threats
T
- TAG – Therapeutic Advisory Group
- TGA – Therapeutic Goods Administration (Australia) - tga.gov.au
- TOC – Table of Contents
- TOPRA – The Organisation for Professionals in Regulatory Affairs
- TPP – Target Product Profile
V
- VAI – Voluntary Action Indicated